SARS-CoV-2 vaccination and attenuation of breakthrough infection severity: A systematic global review and meta-analysis

Clicks: 1
ID: 315436
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #498 of 531 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 531 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background COVID-19 vaccines provide strong protection against severe outcomes but do not fully prevent infection, and the extent to which they attenuate disease severity among breakthrough infections remains unclear. Existing evidence is limited by small sample sizes, potential selection bias, and inconsistent findings. Methods We conducted a systematic selection and meta-analysis of studies identified from a living systematic review of global observational studies reporting vaccine effectiveness (VE) against symptomatic infection and hospitalization. We computed the relative VE (rVE) against hospitalization versus symptomatic infection for matched VE pairs, representing vaccine-induced attenuation of severity. Multilevel meta-analysis and meta-regression were used to pool estimates and assess effect modifiers. Results A total of 184 VE pairs from 37 studies were included. The pooled rVE was 51% (95% CI: 39%, 60%) for broadly defined symptomatic infection and 19% (95% CI: 12%, 25%) for medically attended symptomatic infection, indicating significant attenuation of disease severity among vaccinated cases. Given substantial heterogeneity, interpretation focused on stratified and adjusted analyses. Attenuation was lower in older adults aged ≥60 years and showed no significant waning over time. Variant patterns differed by endpoint definition: attenuation was weaker for Omicron subvariants when broadly defined symptomatic infection was the comparator. No significant differences were observed between vaccine platforms. Conclusions COVID-19 vaccination markedly reduces the risk of progression from symptomatic infection to hospitalization. Attenuation of severity was sustained over time and did not differ significantly by vaccine platform, but was lower in older adults and varied by symptomatic-infection definition and variant period.
Reference Key
openalex_W7163014405 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Caifen Liu, George N. Okoli, R Y L Chen, Sheena G Sullivan, Benjamin J. Cowling
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag346
URL
https://doi.org/10.1093/cid/ciag346
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.